# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 03-08-2024 | 12-31-2023 | 10-K | |
2 | 11-09-2023 | 09-30-2023 | 10-Q | |
3 | 08-10-2023 | 06-30-2023 | 10-Q | |
4 | 05-10-2023 | 03-31-2023 | 10-Q | |
5 | 03-30-2023 | 12-31-2022 | 10-K |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
FDA designation provides potentially seven years of market exclusivity after approval and expanded partnering opportunities for...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy and maintains $3 ...
Cadrenal Therapeutics, Inc., (NASDAQ:CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reve...
Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results.